For the first time in more than 15 years, the FDA has approved a systemic antibacterial drug with a novel mechanism of action to combat community-acquired bacterial pneumonia (CABP).
Lefamulin, which is marketed in oral and intravenous (IV) formulations as Xenleta, is indicated for adults with CABP. The drug is a semisynthetic pleuromutilin that inhibits prokaryotic ribosomal protein synthesis through a unique mechanism that reduces its likelihood of developing resistance to bacteria or cross-resistance with the β-lactam, fluoroquinolone, glycopeptide, macrolide, and tetracycline antibiotic classes.
Voelker R. New Antibiotic for Community-Acquired Pneumonia. JAMA. 2019;322(13):1246. doi:https://doi.org/10.1001/jama.2019.15179
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: